Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8411053 | Drug Discovery Today: Disease Models | 2016 | 7 Pages |
Abstract
Childhood cancer represents a diverse group of malignancies that overall constitute approximately one percent of human cancer. With current multimodality therapies comprising surgery, radiation therapy and intensive chemotherapy, about seventy percent of children are cured of disease, and the 5-year Event-Free survival is approaching 80%. However, gains from current cytotoxic therapies come with a severe cost to the health of survivors. These rare cancers present unique challenges to developing new therapies, in part because relatively few clinical trials can be undertaken. Hence, developing preclinical models that accurately predict responsiveness to new agents assumes an increased importance. Here we review recent advances in preclinical models for development of molecularly targeted therapies.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Raushan T. Kurmasheva, Peter J. Houghton,